NeuroPace (NPCE)
(Delayed Data from NSDQ)
$6.77 USD
-0.51 (-7.01%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $6.79 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
NeuroPace, Inc. (NPCE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.33 | $20.00 | $8.00 | 124.31% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for NeuroPace, Inc. comes to $16.33. The forecasts range from a low of $8.00 to a high of $20.00. The average price target represents an increase of 124.31% from the last closing price of $7.28.
Analyst Price Targets (6 )
Broker Rating
NeuroPace, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NPCE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | SVB Securities | Michael Kratky | Strong Buy | Strong Buy |
5/6/2024 | Lake Street Capital Markets | Frank Takkinen | Strong Buy | Strong Buy |
3/14/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Hold | Strong Buy |
3/6/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $16.33 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.28 |